Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSN ephedra insurance

This article was originally published in The Tan Sheet

Executive Summary

Garden State Nutritionals will continue to carry product liability coverage for its ephedra products, contrary to a report in 1"The Tan Sheet" Dec. 23, 2002, In Brief. Although it retains insurance, Health & Nutrition Systems still plans to cease marketing ephedra supplements due to "overwhelming negative press" on herbal ingredient...

You may also be interested in...



Health & Nutrition Systems

West Palm Beach, Fla.-based firm will discontinue sales of ephedra products because supplier Garden State Nutritionals lost product liability insurance, HNS says Dec. 19. GSN reported in September plans to phase in ephedra-free offerings, but said it still intended to sell the botanical (1"The Tan Sheet" Sept. 9, 2002, p. 4). HNS expects an 18% drop in quarterly sales due to the announcement, noting 19% of 2002 sales came from ephedra-based products, such as Thin Tabs, Fat Cutter Plus. Company retains $10 mil. of liability insurance. Plans to release clinically-tested-for-safety ephedra product with single-dose packaging have been shelved, but firm may launch "after dust settles" on the ingredient...

UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel